Bolt Biotherapeutics, Inc. (BOLT) Ownership
BOLT ownership summary
as of October 18, 2026- Institutions
- 27.9% of shares outstanding
- Insiders
- 3.46% of shares outstanding
- Shares outstanding
- 1.9M
- Float
- 1.6M shares available to trade
- Short interest
- 1.34% 26K shares short
- Days to cover
- 0.72 short interest up 39.2% vs prior month
- Institutions 27.92%
- Insiders 3.46%
- Other investors 68.61%
BOLT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Sofinnova Ventures | 7.15% | 138K | $550,884 | — | June 30, 2026 |
| 2 | Renaissance Technologies Corp | 5.12% | 99K | $394,500 | +21,400 (+27.7%) | June 30, 2026 |
| 3 | Vivo Capital, LLC | 3.76% | 72K | $289,656 | — | June 30, 2026 |
| 4 | Citadel Advisors Llc | 2.95% | 57K | $227,612 | +46,794 (+462.9%) | June 30, 2026 |
| 5 | T3 Companies, LLC | 1.97% | 38K | $152,000 | — | June 30, 2026 |
| 6 | Board of Ttees Leland Stanford Jr Univ | 1.87% | 36K | $143,908 | — | March 31, 2026 |
| 7 | Pfizer Inc | 1.63% | 31K | $125,220 | — | June 30, 2026 |
| 8 | Lynx1 Capital Management, LP | 1.60% | 31K | $123,200 | — | June 30, 2026 |
| 9 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 1.43% | 28K | $110,000 | — | June 30, 2026 |
| 10 | Geode Capital Management, LLC | 0.99% | 19K | $76,476 | −9,672 (−33.6%) | June 30, 2026 |
| 11 | Shay Capital LLC | 0.80% | 15K | $61,752 | +533 (+3.6%) | June 30, 2026 |
| 12 | BlackRock Inc | 0.50% | 9,711 | $38,844 | — | June 30, 2026 |
| 13 | Vanguard Capital Management, LLC | 0.37% | 7,060 | $28,240 | — | June 30, 2026 |
| 14 | Nan Fung Group Holdings Ltd | 0.26% | 5,000 | $20,000 | −24,250 (−82.9%) | June 30, 2026 |
| 15 | Morgan Stanley - Brokerage Accounts | 0.16% | 3,145 | $12,580 | −44 (−1.4%) | June 30, 2026 |
| 16 | Vanguard Fiduciary Trust Co | 0.16% | 3,095 | $12,380 | — | June 30, 2026 |
| 17 | Goss Wealth Management LLC | 0.13% | 2,530 | $10,120 | +2,530 (0.0%) | June 30, 2026 |
| 18 | Tower Research Capital LLC | 0.09% | 1,710 | $6,840 | +617 (+56.5%) | June 30, 2026 |
| 19 | Mercer Global Advisors Inc. | 0.02% | 292 | $1,168 | +292 (0.0%) | June 30, 2026 |
| 20 | UBS Group AG | 0.01% | 255 | $1,020 | −532 (−67.6%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 6 holders added 72K shares and 4 cut 34K.
BOLT top mutual fund and ETF holders
6 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Extended Market Index | 0.39% | 7,466 | $29,864 | −40 (−0.5%) | August 31, 2026 |
| 2 | Fidelity Total Market Index | 0.28% | 5,348 | $21,392 | — | August 31, 2026 |
| 3 | Fidelity Series Total Market Index | 0.09% | 1,699 | $6,796 | — | August 31, 2026 |
| 4 | BlackRock Diversified Equity Alpha Inst | <0.01% | 89 | $356 | — | June 30, 2026 |
| 5 | BSF Systematic US Eq Abs Ret A2 USD | <0.01% | 62 | $248 | — | December 31, 2025 |
| 6 | Guggenheim Active Allocation Fund | <0.01% | 12 | $48 | +6 (+100.0%) | May 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
BOLT insider transactions
latest 4| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-05 | Sarah Nemec | Buy | $4.61 | 125 | $576 |
| 2025-12-05 | William P Quinn | Buy | $4.61 | 125 | $576 |
| 2025-06-06 | Sarah Nemec | Buy | $5.49 | 125 | $686 |
| 2025-06-06 | William P Quinn | Buy | $5.49 | 125 | $686 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
BOLT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns BOLT
Institutional investors own 27.9% of Bolt Biotherapeutics's shares and insiders 3.46%. The largest holder is Sofinnova Ventures with 7.15% of the shares (138K), as of June 30, 2026. Among the top 20 institutions, 6 added shares and 4 reduced their stake in the latest filings. Short interest is 1.34% of the float, or 0.72 days of average trading volume. The share count rose 167.3% since 2019.
Related: BOLT analyst forecast, BOLT key metrics. See the BOLT stock overview for the latest quote and news.
BOLT ownership FAQ
Who owns the most Bolt Biotherapeutics stock?
The largest shareholders of Bolt Biotherapeutics are Sofinnova Ventures (7.15%), Renaissance Technologies Corp (5.12%), Vivo Capital, LLC (3.76%), Citadel Advisors Llc (2.95%), T3 Companies, LLC (1.97%).
What percentage of Bolt Biotherapeutics is owned by institutions?
Institutions hold 27.9% of Bolt Biotherapeutics's shares outstanding; insiders hold 3.46%.
Which funds own Bolt Biotherapeutics?
The largest fund holders of Bolt Biotherapeutics are Fidelity Extended Market Index (0.39%), Fidelity Total Market Index (0.28%), Fidelity Series Total Market Index (0.09%), BlackRock Diversified Equity Alpha Inst (<0.01%), BSF Systematic US Eq Abs Ret A2 USD (<0.01%).
What is Bolt Biotherapeutics's short interest?
26K shares of Bolt Biotherapeutics were sold short, 1.34% of the float; at the average daily volume it would take 0.72 days to cover.
Are insiders buying or selling Bolt Biotherapeutics?
Of the latest 4 reported insider transactions in Bolt Biotherapeutics (since June 6, 2025), 4 were purchases and 0 were sales.
How many shares of Bolt Biotherapeutics are outstanding?
Bolt Biotherapeutics has 1.9M shares outstanding, of which 1.6M are in the public float.